$Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience$

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of i...

Full description

Bibliographic Details
Main Authors:	Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	neuroblastoma relapsed refractory dinutuximab beta anti-GD2
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full

Similar Items

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Aleksandra Wieczorek, et al.
Published: (2022-04-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
by: Holger N. Lode, et al.
Published: (2023-06-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
by: Adeiye A. Pilgrim, et al.
Published: (2023-12-01)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

HIGH GRADE GLIOMA OF CENTRAL NERVOUS SYSTEM: SINGLE CENTER TREATMENT EXPERIENCE
by: Nur OLGUN, et al.
Published: (2021-11-01)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
by: Tim Flaadt, et al.
Published: (2023-09-01)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
by: Sascha Troschke-Meurer, et al.
Published: (2023-01-01)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
by: Stefano Mastrangelo, et al.
Published: (2021-11-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
by: Claudia Paret, et al.
Published: (2022-12-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
by: Aleksandra Wieczorek, et al.
Published: (2023-08-01)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD<sub>2</sub> Antibody Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2022-10-01)

Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies
by: Tekincan Aktas, et al.
Published: (2023-08-01)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
by: Arthur Wingerter, et al.
Published: (2021-01-01)

Infantile Hemangiomas of the Head and Neck: A Single-Center Experience
by: Deniz Kizmazoglu, et al.
Published: (2024-03-01)

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice
by: Sidra Maqbool, et al.
Published: (2019-02-01)

Monitoring Immune Responses in Neuroblastoma Patients during Therapy
by: Celina L. Szanto, et al.
Published: (2020-02-01)

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
by: Xin‐Yuan Liu, et al.
Published: (2022-09-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

Comparing Tribbles Homolog 3 (TRIB3) Protein Expression Levels with Clinicopathological Characteristics and Survival Among Neuroblastoma Patients
by: Burçin Baran, et al.
Published: (2023-09-01)

Bilateral Breast Cancer with Neurofibromatosis Type 1 Patient: Case Report
by: Duygu Dursun, et al.
Published: (2017-10-01)

Effect of Ecklonia Cava Polyphenol Extract in House Ear Institute-Organ of Corti 1 Cells Against Cisplatin Ototoxicity: A Preliminary Study
by: Ufuk Düzenli, et al.
Published: (2016-12-01)

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
by: Hunter C. Jonus, et al.
Published: (2022-12-01)

Comments on ‘Coexistence of diaphragm eventration and multiple organ anomalies after sigmoid volvulus’
by: Sabri Selçuk Atamanalp
Published: (2019-12-01)

Whole Exome Sequencing Analysis of Good and Bad Prognostic Neuroblastoma Patients (on the Behalf of Turkish Pediatric Oncology Group)
by: Zekiye Altun, et al.
Published: (2018-12-01)

Risk factors, physical and mental health burden of male and female pathological gamblers in the German general population aged 40–80
by: Martin Wejbera, et al.
Published: (2021-03-01)

Novel Gd(OH)3, GdOOH and Gd2O3 Nanorods: Microwave-Assisted Hydrothermal Synthesis and Optical Properties
by: Maciel Salomão de Almeida, et al.
Published: (2016-08-01)

The microstructure and mechanical properties of Mg-Gd-Y-Zn-Zr system and Mg-Gd-Y-Zr system alloys by RUE deformation
by: Leichen Jia, et al.
Published: (2021-01-01)